[KO Validated] Cleaved Gasdermin E (N-terminal) Rabbit Monoclonal Antibody for WB, IHC-P, ELISA - O60443

Core Product Specifications and Parameters

Biological Background: Gasdermin E Function and Localization

• Gasdermin E (GSDME), also known as DFNA5 or ICERE-1, is a member of the gasdermin family of pore-forming proteins. It is expressed as a precursor that is cleaved to release an active N-terminal fragment, with multiple isoforms produced by alternative splicing.
• Upon cleavage by caspase-3 (CASP3) or granzyme B (GZMB) at Asp270, the N-terminal fragment translocates to the plasma membrane, oligomerizes, and forms pores of 10–15 nm inner diameter, triggering pyroptosis and the release of inflammatory cytokines such as IL-1β and IL-16. Related references: PMID:27281216, PMID:28459430, PMID:32188940, PMID:33852854
• GSDME-mediated pyroptosis acts as a tumor suppression mechanism: granzyme B delivered by natural killer (NK) cells cleaves GSDME in tumor cells, inducing pyroptosis and robust anti-tumor immunity. Related references: PMID:21522185, PMID:32188940, PMID:31953257
• Downstream of the mitochondrial apoptotic pathway and DNA damage, GSDME can switch apoptosis to secondary necrosis and pyroptosis, partially via p53/TP53 signaling. Related references: PMID:28045099, PMID:16897187
• GSDME exhibits bactericidal activity and promotes pyroptosis in response to microbial infections, including Zika virus-induced placental pyroptosis that impacts fetal outcomes. Related references: PMID:27281216
• In terms of subcellular localization, full-length GSDME is primarily cytoplasmic, while the cleaved N-terminal fragment localizes to the cell membrane where it forms pores.
• GSDME is expressed in the cochlea and at low levels in many tissues, with highest expression in the placenta. Mutations in the gene are associated with autosomal dominant non-syndromic hearing impairment. Related references: PMID:9771715
• Post-translational modifications, including palmitoylation and isopeptide bond formation, may regulate GSDME activation and membrane insertion.

Experimental Guidance and Technical Tips

• The antibody’s immunogen is designed around the Asp270 cleavage site, making it specific for the N-terminal fragment. Validate specificity in your experimental system using appropriate positive and negative controls (e.g., untreated vs. apoptosis/pyroptosis inducers).
• For Western blot, expect multiple bands due to uncleaved precursor (~55 kDa) and cleaved fragments (N-terminal at ~11 kDa and 35 kDa, depending on isoform). Optimize loading and detection conditions to distinguish these forms.
• For IHC-P, perform antigen retrieval and test dilution series to achieve optimal staining. The antibody has been validated for human samples; cross-reactivity with other species is not reported, so confirm reactivity if using non-human tissues.
• For ELISA, consider pairing with a C-terminal-specific antibody for sandwich ELISA to quantify cleaved GSDME. Run pilot experiments to establish sensitivity and dynamic range.
• In pyroptosis studies, monitor cleavage as a readout; combine with caspase-3 activity assays or granzyme B detection for mechanistic insights.

CamelBio: Your One-Stop Sourcing Bridge

CamelBio is a comprehensive provider of IVD raw materials, offering validated antibodies, antigens, and ancillary reagents for diagnostic and research applications. This Gasdermin E antibody supports investigations into pyroptosis, tumor immunology, and hearing disorders. Whether you need bulk supply, customized antibody development, or rare target sourcing, CamelBio’s integrated platform streamlines procurement from discovery to clinical translation.